Moderna Clinical Trial Data Confirm Its Updated COVID-19 Vaccine Generates Robust Immune Response In Humans Against Widely Circulating Variants
Portfolio Pulse from Benzinga Newsdesk
Moderna has confirmed that its updated COVID-19 vaccine generates a robust immune response against widely circulating variants, including EG.5 and FL 1.5.1. The updated vaccine is expected to be available in the coming weeks for the fall vaccination season, pending approval.
August 17, 2023 | 8:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Moderna's updated COVID-19 vaccine, which has shown a strong immune response against key variants, is expected to be available soon. This could potentially boost the company's revenues and stock price.
The news of Moderna's updated COVID-19 vaccine showing a robust immune response against key variants is directly related to the company's core business. If the vaccine is approved and becomes available as expected, it could lead to increased revenues for Moderna, which could positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100